Therapeutics Pipeline

Lauren Sauer; Alice Sato; Herbert Dele Davies

doi:10.1016/j.pcl.2024.03.002

Therapeutics Pipeline

Pediatr Clin North Am. 2024 Jun;71(3):481-498. doi: 10.1016/j.pcl.2024.03.002.

Authors

Lauren Sauer¹, Alice Sato², Herbert Dele Davies³

Affiliations

¹ GCHS, Special Pathogen Research Network, Department of Environmental, Agricultural and Occupational Health, UNMC College of Public Health, 984355 Nebraska Medical Center, Omaha, NE, USA.
² Department of Pediatrics, Division of Pediatric Infectious Disease, University of Nebraska Medical Center, 987810, Nebraska Medical Center, Omaha, NE 68198-7810, USA.
³ Department of Pediatrics, Division of Pediatric Infectious Disease, University of Nebraska Medical Center, 987810, Nebraska Medical Center, Omaha, NE 68198-7810, USA; Academic Affairs, University of Nebraska Medical Center, 987810 Nebraska Medical Center, Omaha, NE 68198-7810, USA. Electronic address: [email protected].

PMID: 38754937
DOI: 10.1016/j.pcl.2024.03.002

Abstract

Children have unique physiologic, developmental, and psychosocial needs and unique vulnerabilities, making them a challenging population for which to develop therapeutics. This is particularly apparent in the urgent and chaotic environment of a pandemic or outbreak. Advances in the development of medical countermeasures (MCMs) for pediatric populations have grown substantially over the last decade, and the coronavirus disease 2019 pandemic forced advancements in how we approach pediatric MCM development. Consequently, a MCMs pipeline targeting the pediatric population is essential. This article addresses the challenges inherent in these differences that must be taken into account.

Keywords: Antivirals; Drug pipeline; Formulations; Medical countermeasures; Monoclonal antibodies; Physiology; Polyclonal preparations; Therapeutics.

Publication types

Review

MeSH terms

COVID-19 Drug Treatment
COVID-19* / epidemiology
Child
Humans
Pandemics
SARS-CoV-2